Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health, Inc. reports developments tied to its medical technology portfolio, commercial agreements and capital structure. The company focuses on life-saving and life-enhancing medical solutions through acquired or developed assets, intellectual property and technologies. Recent company updates include exclusive worldwide marketing and distribution rights for BreastCheck™ through Odyssey Medical Devices, development work on the patented Save A Life choking rescue device, and commercial service arrangements intended to add recurring revenue.
Odyssey Health news also includes financing facilities, promissory-note activity, operating and financial results, shareholder voting matters, and completed portfolio transactions such as the sale of its neurological drug-therapy assets related to concussion, Niemann Pick Disease Type C, powder formulation technology and a nasal delivery device.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Odyssey Health, Inc. (OTC: ODYY) has announced the launch of a concept phase for an intra-nasal antidote targeting organophosphate nerve agents, a significant global threat. The innovative device aims to deliver medication directly to the brain through the olfactory nerve, potentially providing immediate protection against nerve gas exposure. Unlike traditional auto-injectors, the new delivery method is designed to minimize pain and risk of infection, offering faster and more effective treatment. With increasing concerns about chemical warfare, particularly in conflict zones like Ukraine, this development addresses a critical need for accessible and effective medical solutions.
Odyssey Health, Inc. (OTC: ODYY) provided a company update, emphasizing progress in developing life-enhancing medical products. The highlight is a successful Phase I clinical trial for a concussion drug, with preparations for Phase II underway. The global concussion treatment market, valued at $6.9 billion in 2020, is expected to grow to $8.9 billion by 2027. Odyssey also announced plans for a nerve agent antidote, a choking rescue device, and a rapid EKG tool, while raising over $5 million and reducing share dilution.
Odyssey Health, Inc. (OTC: ODYY) provides a significant update on its concussion drug development program, which addresses a global medical need. Since acquiring the drug's rights in March 2021, the company has made notable advancements, including:
- Completion of a Phase I clinical trial proving safety and tolerability.
- Development of a novel breath-propelled intranasal delivery device.
- Raised over $5 million to support ongoing efforts and secured access to an equity line of up to $10 million.
Odyssey aims to transform concussion treatment with its synthetic neurosteroid.
Odyssey Health, Inc. (OTC: ODYY) will hold its Annual Meeting of Stockholders on January 12, 2023. To participate, stockholder proposals must be submitted by November 25, 2022, to the corporate offices in Las Vegas. The proposals should comply with company bylaws. Odyssey is focused on developing unique medical products and solutions with significant market potential. The company emphasizes creating and acquiring distinct assets and technologies that enhance clinical utility.
Odyssey Health, Inc. (OTC: ODYY) is strengthening its commitment to Odyssey NeuroPharma with key executive appointments, including Erik Emerson as Chief Commercial Officer and Greg Gironda as Chief Operating Officer. Both executives bring over 50 years of combined experience in the pharmaceutical sector. Odyssey NeuroPharma aims to address unmet medical needs in traumatic brain injury, planning a Phase II clinical trial to evaluate treatment efficacy. Currently, no FDA-approved treatments exist for concussions, which affect over 5 million people in the U.S. annually.
Odyssey Health, Inc. (OTC: ODYY) has filed for patent protection for its innovative intranasal brain-drug delivery device, designed to treat concussions. The recently completed Phase I study confirmed the safety and effectiveness of using this device with Odyssey's concussion drug, PRV-002, on 40 healthy volunteers. The study observed no device failures, indicating strong performance. This technology aims to enhance drug delivery for central nervous system conditions, potentially leading to significant market opportunities in the healthcare sector.